Supplementary materials: Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam in the long-term care setting in the USA

dataset

posted on 2024-05-03, 16:17 authored by Darshan Mehta, Inyoung Lee, Hangcheng Liu, Mitchell DeKoven, Brian Wensel, G Rhys Williams

These are peer-reviewed supplementary materials for the article 'Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam in the long-term care setting in the USA' published in the Journal of Comparative Effectiveness Research.

Supplementary Table S1: Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis by ASM cohort
Supplementary Table S2: Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis stratified by IDD, by ASM cohort
Supplementary Table S3: Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis stratified by age ≥ 65 years, by ASM cohort
Supplementary Table S4: Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis stratified by 0–1 prior ASMs, by ASM cohort
Supplementary Table S5: Baseline clinical characteristics for patients with any epilepsy or seizure diagnosis by ASM cohort, pre and post-IPTW
Supplementary Table S6: Baseline clinical characteristics of patients with any epilepsy or seizure diagnosis stratified by IDD, by ASM cohort
Supplementary Table S7: Baseline clinical characteristics for patients with any epilepsy or seizure diagnosis stratified by age ≥ 65 years, by ASM cohort
Supplementary Table S8: Baseline clinical characteristics of patients with any epilepsy or seizure diagnosis stratified by 0–1 prior ASMs
Supplementary Table S9: All-cause and epilepsy-specific healthcare costs over the post-index period in patients with any epilepsy or seizure diagnosis, by ASM cohort
Supplementary Figure S1: Sensitivity analysis: Key inclusion and exclusion criteria for patients with any epilepsy or seizure diagnosis
Supplementary Figure S2: Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis in (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results post-IPTW)
Supplementary Figure S3: Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis with IDD in (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results)
Supplementary Figure S4: Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis among patients aged ≥ 65 years in (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results)
Supplementary Figure S5: Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis among patients with 0–1 prior ASMs (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results)

Aim: To compare all-cause and epilepsy-specific pharmacy and total costs associated with initiation of eslicarbazepine acetate (ESL) or brivaracetam (BRV) among patients with focal seizures in long-term care (LTC) in theUS. Methods: This retrospective analysis used data from IQVIA’s New DataWarehouse. Results: 298 patients initiated ESL and 282 patients initiated BRV. Initiation of ESL versus BRV was associated with 33.3% lower all-cause pharmacy costs, 34.4% lower epilepsy-specific pharmacy costs, 21.3% lower all-cause total costs and 30.9% lower epilepsy-specific total costs (all p < 0.0001). Conclusion: Among patients with focal seizures in LTC in the US, initiation of ESL versus BRV was associated with significant reductions in all-cause and epilepsy-specific pharmacy and total costs compared with initiation of BRV.